α2-Adrenoceptors are targets for antipsychotic drugs

Psychopharmacology

Volumn 231, Issue 5, 2014, Pages 801-812

  Brosda, Jan ^a   Jantschak, Florian ^a,b   Pertz, Heinz H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Federal Joint Committee   (Germany)

Author keywords

2 Adrenoceptor antagonists; 2 Adrenoceptor agonists; D2 receptor antagonists; Nucleus accumbens; Prefrontal cortex; Schizophrenia

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 4 AMINOBUTYRIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CLONIDINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; GLUTAMIC ACID; GUANFACINE; HALOPERIDOL; IDAZOXAN; MIRTAZAPINE; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PIMAVANSERIN; PLACEBO; POMAGLUMETAD METHIONIL; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN; TERGURIDE; YOHIMBINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANXIETY; AVOIDANCE BEHAVIOR; BINDING AFFINITY; BLOOD PRESSURE; COGNITIVE DEFECT; CORPUS STRIATUM; DELUSION; DOPAMINE RELEASE; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; NEGATIVE SYNDROME; NONHUMAN; NORADRENALIN UPTAKE; OPTIMAL DRUG DOSE; PARKINSON DISEASE; POSITIVE SYNDROME; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEDATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WORKING MEMORY; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, ADRENERGIC, ALPHA-2; SCHIZOPHRENIA;

EID: 84896715449     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3459-8     Document Type: Review

References (162)

1. Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S (2010) The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 116:101-106
2. Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7(Suppl 1):S1-S5
3. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97:8104-8109
4. 1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719
5. Adell A, Jiménez-Sánchez L, López-Gil X, Romón T (2012) Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr Bull 38:9-14
6. 1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 84:193-196
7. 2A-adrenergic receptor-like immunoreactivity. Brain Res 650:181-204
8. Aoki C, Venkatesan C, Go CG, Forman R, Kurose H (1998) Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons. Cereb Cortex 8:269-277
9. Arnsten AF (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berlin) 174:25-31
10. 2-Adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230:1273-1276
11. 2-receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging 14:597-603
12. Arnsten AF, Jin LE (2012) Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 85:45-58
13. 2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 8:4287-4298
14. Autry AE, Monteggia LM (2012) Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 64:238-258
15. Baldessarini RJ, Tarazi FJ (2006) Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 461-500
16. Berk M, Ichim C, Brook S (2001) Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16:87-92
17. Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S (2009) Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 24:233-238
18. 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. Eur J Neurosci 63:293-298
19. Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, Kerwin RW (2000) No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 280:65-68
20. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-528
21. 2C, inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109:819-826
22. Caforio G, Di Giorgio A, Rampino A, Rizzo M, Romano R, Taurisano P, Fazio L, De Simeis G, Ursini G, Blasi G, Nardini M, Mancini M, Bertolino A (2013) Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia. J Clin Psychopharmacol 33:810-812
23. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070
24. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:165-173
25. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260
26. 2- Noradrenergic receptors activation enhances excitability and synaptic integration in rat prefrontal cortex pyramidal neurons via inhibition of HCN currents. J Physiol 584:437-450
27. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE, Suh S, Yook KH, Lee SH (2011) Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 35:208-211
28. Chou YH, Halldin C, Farde L (2006) Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berlin) 185:29-35
29. Christie MJ, Bridge S, James LB, Beart PM (1985) Excitotoxin lesions suggest an aspartatergic projection from rat medial prefrontal cortex to ventral tegmental area. Brain Res 333:169-172
30. Clark DA, Mata I, Kerwin RW, Munro J, Arranz MJ (2007) No association between ADRA2A polymorphisms and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B:341-343
31. Devoto P, Flore G (2006) On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Curr Neuropharmacol 4:115-125
32. Devoto P, Flore G, Pira L, Longu G, Gessa GL (2004) Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol 487:105-111
33. 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn Schmiedeberg's Arch Pharmacol 343:472-477
34. 2C-adrenoceptors in the human striatum. Synapse 62:508-515
35. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
36. Felder CC, McKinzie DL, Thompson RC, Liu B (2012) Muscarinic acetylcholine receptors as novel targets for the development of therapeutics for schizophrenia. In: Albert JS, Wood MW (eds) Targets and emerging therapies for schizophrenia, 1st edn. Wiley, New York, pp 355-379
37. Fernández J, Alonso JM, Andrés JI, Cid JM, Díaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA (2005) Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem 48:1709-1712
38. Fields RB, Van Kammen DP, Peters JL, Rosen J, Van Kammen WB, Nugent A, Stipetic M, Linnoila M (1988) Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. Schizophr Res 1:417-423
39. 2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 22:8771-8777
40. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040-1047
41. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL (2001) Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 25:402-409
42. 2 receptors for antipsychotic activity. Handb Exp Pharmacol 212:27-52
43. Goldman-Rakic PS, Brown RM (1981) Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 6:177-187
44. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berlin) 174:3-16
45. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30:220-227
46. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
47. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, The WFSBP Task Force on Treatment Guidelines for Schizophrenia (2012) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318-378
48. Hecht EM, Landy DC (2012) Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res 134:202-206
49. Hertel P, Nomikos GG, Svensson TH (1999a) Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur J Pharmacol 371:153-158
50. 2 adrenoceptor blockade. Science 286:105-107
51. 3H] rauwolscine. Neuroscience 117:875-898
52. Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496-11500
53. Horn AS (1973) Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates. Br J Pharmacol 47:332-338
54. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 35:549-562
55. Hurley KM, Herbert H, Moga MM, Saper CB (1991) Efferent projections of the infralimbic cortex of the rat. J Comp Neurol 308:249-276
56. 2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett 454:143-147
57. h) in neurons of the ventral tegmental area. Neuroscience 167:287-297
58. 2 receptor antagonist raclopride on conditioned avoidance responding in rats. Behav Pharmacol 21:654-659
59. 2C-adrenergic receptors, and its antipsychotic-like effects in rats. J Pharmacol Exp Ther 347:57-68
60. 1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312
61. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J (2009) Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 108:245-251
62. Jones BE, Halaris AE, McIlhany M, Moore RY (1977) Ascending projections of the locus coeruleus in the rat. I. Axonal transport in central noradrenaline neurons. Brain Res 127:1-21
63. 2A-Adrenoceptors regulate d-amphetamine-induced hyperactivity and behavioural sensitization in mice. Eur J Pharmacol 517:74-83
64. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33-40
65. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
66. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090
67. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873-883
68. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A (2006) One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81:1-15
69. 18F]fallypride positron emission tomography. Biol Psychiatry 68:634-641
70. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M (2010b) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231-239
71. Koch M (2007) On the effects of partial agonists of dopamine receptors for the treatment of schizophrenia. Pharmacopsychiatry 40:1-6
72. Krystal JH, McDougle CJ, Woods SW, Price LH, Heninger GR, Charney DS (1992) Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology (Berl) 108:313-319
73. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
74. 2A-adrenergic receptor knockout mice. Neuroscience 113:289-299
75. Lähdesmäki J, Sallinen J, MacDonald E, Scheinin M (2004) Alpha2A-adrenoceptors are important modulators of the effects of D-amphetamine on startle reactivity and brain monoamines. Neuropsychopharmacology 29:1282-1293
76. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
77. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951-962
78. 2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci U S A 90:8861-8865
79. Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334
80. Li BM, Mei ZT (1994) Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol 62:134-139
81. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
82. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571-579
83. 1 receptor mRNA in projections from the forebrain to the ventral tegmental area. Synapse 25:205-214
84. 2- adrenoceptors in monkeys. Neuroreport 14:1013-1016
85. Maas JW, Miller AL, Tekell JL, Funderburg L, Silva JA, True J, Velligan D, Berman N, Bowden CL (1995) Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. J Clin Psychopharmacol 15:361-364
86. Mao ZM, Arnsten AF, Li BM (1999) Local infusion of an α-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry 46:1259-1265
87. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH (2005) Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315-327
88. 2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13:891-903
89. Masana M, Bortolozzi A, Artigas F (2011) Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neuropsychopharmacol 14:53-68
90. McCreary AC, Jones CA (2010) Antipsychotic medication: the potential role of 5-HT1A receptor agonism. Curr Pharm Des 16:516-521
91. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15:17-29
92. Meltzer HY (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol 212:87-124
93. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393-406
94. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197
95. Meltzer HY, Massey BW (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11:59-67
96. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
97. 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35:881-892
98. Meltzer HY, Massey BW, Horiguchi M (2012a) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in Schizophrenia. Curr Pharm Biotechnol 13:1572-1586
99. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012b) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res 141:144-152
100. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (2000) Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12:1079-1095
101. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804
102. Morrison JH, Molliver ME, Grzanna R, Coyle JT (1981) The intra-cortical trajectory of the coeruleo-cortical projection in the rat: a tangentially organized cortical afferent. Neuroscience 6:139-158
103. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH (1993) Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157:53-56
104. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2011) Partial agonists in schizophrenia - why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14:1165-1178
105. 1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11:802-812
106. Nicholas AP, Pieribone V, Hökfelt T (1993) Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 328:575-594
107. Nicholas AP, Hökfelt T, Pieribone VA (1996) The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci 17:245-255
108. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
109. Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21:389-390
110. Olbrich R, Schanz H (1991) An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect 84:233-236
111. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
112. Oranje B, Glenthøj BY (2013) Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. Schizophr Bull 39:684-691
113. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107
114. Porsolt RD, Moser PC, Castagné V (2010) Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 333:632-638
115. Raiteri M, Del Carmine R, Bertollini A, Levi G (1977) Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol 41:133-143
116. Ramos BP, Arnsten AF (2007) Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 113:523-536
117. 2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem 13:770-776
118. Remington G, Agid O, Foussias G (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother 11:589-607
119. 2 mechanisms of action. In: Ritsner MS (ed) Polypharmacy in psychiatry practice, vol I: multiple medication use strategies. Springer, Berlin, pp 157-210
120. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359
121. Rung JP, Carlsson A, Rydén Markinhuhta K, Carlsson ML (2005) (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:827-832
122. 2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 18:3035-3042
123. 2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150:391-402
124. 2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113:239-249
125. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426-437
126. 2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 84:193-205
127. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, Fremeau RT Jr (1994) Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21:133-149
128. 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrinology 22:177-188
129. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
130. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin) 124:57-73
131. Schutz G, Berk M (2001) Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16:275-278
132. 2 receptor in schizophrenia. Expert Opin Ther Targets 10:515-531
133. Seeman P (2013) Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol 23:999-1009
134. Sesack SR, Pickel VM (1992) Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 320:145-160
135. Simpson EH, Kellendonk C, Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65:585-596
136. Sommer IE, Begemann MJ, Temmerman A, Leucht S (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003-1011
137. Stahl SM (2009) Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr 14:71-73
138. Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA (2012) Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany. J Clin Psychopharmacol 32:602-607
139. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G (2010) Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol 13:433-441
140. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G (2011) More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:1080-1086
141. Svensson TH (2003) α-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145-1158
142. Swanson LW, Hartman BK (1975) The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol 163:467-505
143. Terevnikov V, Stenberg JH, Joffe M, Tiihonen J, Burkin M, Tchoukhine E, Joffe G (2010) More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Hum Psychopharmacol 25:431-438
144. Terwisscha van Scheltinga AF, Bakker SC, Kahn RS, Kas MJ (2013) Fibroblast growth factors in neurodevelopment and psychopathology. Neuroscientist 19:479-494
145. 2C-adrenoceptor-deficient mice. Naunyn Schmiedeberg's Arch Pharmacol 364:117-130
146. Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ (2001) Association analysis of polymorphism in the promoter region of the α2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 49:53-58
147. 3H]MK912 and subtype-selective drugs. Brain Res 770:261-266
148. van den Buuse M, Garner B, Gogos A, Kusljic S (2005) Importance of animal models in schizophrenia research. Aust N Z J Psychiatry 39:550-557
149. Van der Schyf CJ, Youdim MB (2009) Multifunctional drugs as neurotherapeutics. Neurotherapeutics 6:1-3
150. Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S (2013) Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia. Clin Schizophr Relat Psychoses 4:1-24
151. Villégier AS, Drouin C, Bizot JC, Marien M, Glowinski J, Colpaërt F, Tassin JP (2003) Stimulation of postsynaptic α1b- and α2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. Synapse 50:277-284
152. Wadenberg ML, Ericson E, Magnusson O, Ahlenius S (1990) Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biol Psychiatry 28:297-307
153. Wadenberg ML, Wiker C, Svensson TH (2007) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive α2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191-202
154. 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res 1024:176-182
155. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AF (2007) α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129:397-410
156. Weinberger DR, Berman KF, Chase TN (1988) Mesocortical dopaminergic function and human cognition. Ann N Y Acad Sci 537:330-338
157. 2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A 88:1859-1863
158. Weinshenker D, Schroeder JP (2007) There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 32:1433-1451
159. Wikström HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J (2002) Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6- methoxy-2-methyldibenzo[c, f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem 45:3280-3285
160. Wong EH, Tarazi FI, Shahid M (2010) The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol Ther 126:173-185
161. 2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J Pharmacol Exp Ther 289:1286-1292
162. Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23:103-111